Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.

Research output: Contribution to journalArticle

Abstract

5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma. In this phase I study cetuximab was added and the primary aim was to determine the maximum tolerated dose (MTD) of 5FU and MMC in this combination.

Details

Authors
Organisations
External organisations
  • Oslo university hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)2740-2746
JournalEuropean Journal of Cancer
Volume51
Issue number18
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Related research output

Otilia Leon, 2019, Lund: Lund University, Faculty of Medicine. 76 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)